Shots:

• Fujifilm and Opsis to receive $30M up front and ~$40M as R&D and part of manufacturing funding for the development of 3 programs. The companies are eligible to receive development & commercial milestones along with royalties on a per-program basis
• BlueRock to get an option to license the 3 programs on a program-by-program basis and will be responsible for development & commercialization of the licensed products. Fujifilm and BlueRock will share manufacturing responsibilities and commercial supply- with Fujifilm responsible for clinical supply
• The companies will combine their expertise to discover and develop off-the-shelf iPS cell therapies for ocular diseases

  Ref: Bayer | Image: PRNewswire